type: misc

label: url

en: 周術期の血管機能保護戦略

ja: 周術期の血管機能保護戦略

en: Potassium channels play an essential role in the membrane potential of arterial smooth muscle, and also in regulating contractile tone. Especially, in vascular smooth muscle, the opening of adenosine triphosphate(ATP)-sensitive potassium(KATP)channels leads to membrane hyperpolarization, resulting in muscle relaxation and vasodilation. This activation also plays a role in tissues during pathophysiologic events such as ischemia, hypoxia, and vasodilatory shock. In this review, we will describe the physiological and pathophysiological roles of vascular smooth muscle KATP channels in relation to the effects of anesthetics and perioperative managements. Although accumulated evidence suggests that many anesthetics and perioperative managements(especially, diabetes and hyperglycemia)modify the above function of K+ channels as a metabolic sensor. Use of effective volatile anesthetics and the strict glycemic control may contribute to protect perioperative vascular function.

en: Shikoku Acta Medica

ja: 四国医学雑誌


en: 非薬物降圧治療の可能性-RDN, デバイス，遠隔モニタリング

ja: 非薬物降圧治療の可能性-RDN, デバイス，遠隔モニタリング

en: Journal of Clinical and Experimental Medicine

ja: 医学のあゆみ


en: 7 心臓病と肥満 -メタボリックシンドロームを中心に-

ja: 7 心臓病と肥満 -メタボリックシンドロームを中心に-

en: 循環器疾患最新の治療2016-2017(監修 堀 正二，編集 長井 良三，伊藤 浩)


en: 単心室症患児の開心術後にフェイススケールを用いて心臓リハビリテーションを試みた1症例

en: Heart

ja: 心臓


en: 心臓サルコイドーシス再燃に対してメトトレキサートの併用が有効であった1例

ja: 心臓サルコイドーシス再燃に対してメトトレキサートの併用が有効であった1例

en: 心臓サルコイドーシスの標準的治療はステロイドであるが，ステロイドを投与中であっても再燃を認めることも多く，またステロイドの多岐にわたる副作用も問題となることが多い．症例は70歳代，女性．心臓サルコイドーシスの診断でプレドニンを維持量5 mg/日で加療されていた．定期検査で施行した心電図で陰性T波，前壁心尖部に新規の左室壁運動異常を認めた．FDG-PET，Gaシンチグラフィーで壁運動異常部位に一致して集積を認め，心臓サルコイドーシスの再燃と判断した．本症例では，ステロイドの副作用として糖尿病，肥満，白内障などを認めており，ステロイド増量が躊躇され，メトトレキサートの併用を開始した．メトトレキサート開始後，特に副作用を認めず，心電図ならびに左室壁運動異常の改善が認められた．ステロイド投与で再燃を認める心臓サルコイドーシス症例にはメトトレキサート併用も考慮すべきであると考えられた．

en: The Journal of the Japanese Society of Internal Medicine

ja: 日本内科学会雑誌


en: Efficacy of percutaneous transluminal renal angioplasty for renovascular hypertension complicated with heart failure

ja: 心不全を合併した腎血管性高血圧に対する経皮的腎動脈形成術の有効性(第11回若手奨励賞受賞論文)

en: 【Background】 Percutaneous transluminal renal angioplasty (PTRA) is recommended for patients with heart failure due to renovascular hypertension ; however, the clinical characteristics of the patients and the effects of PTRA on heart failure and cardiorenal function have not been elucidated. 【Methods】 We retrospectively analyzed data for 4 PTRA-treated patients (male/female, 1/3 ; mean age, 70.0±10 years ; mean left ventricular ejection fraction, 51.5±15.2%) with heart failure due to renovascular hypertension and evaluated the effects of PTRA on heart failure and cardiorenal function 6 months after treatment. 【Results】 All patients had pro-arteriosclerotic diseases including diabetes mellitus, essential thrombocythemia, heparin cofactor II deficency, metabolic syndrome, and familial hypercholesterolemia, and 3 patients had ischemic heart disease. No abdominal bruit was heard and mean plasma renin activity was 4.5±3.6 ng/ml/hr, which was not elevated, contrary to expectation. All contralateral kidneys of PTRA were nonfunctioning, suggesting bilateral kidneys were disturbed in all patients. In all patients, PTRA was successfully performed and resolved heart failure. PTRA resulted in decreases in systolic blood pressure from 157±18 to 124±8.6 mmHg, mean serum creatinine from 3.2±2.6 to 2.7±2.2 mg/dl, and mean BNP from 919±998 to 243±291 pg/ml at 6 months after treatment. PTRA did not change left ventricular ejection fraction, a parameter of systolic fraction evaluated by an echocardiogram ; however, PTRA improved E/e', a parameter of left ventricular diastolic fraction, from 16.1±5.2 to 9.7±3.7. None of the patients were hospitalized due to heart failure during the 6-month period after PTRA. 【Conclusions】 Patients with heart failure with cardiovascular risk factors should be screened for renovascular hypertension regardless of abdominal bruit or plasma renin activity. PTRA is effective for resolving heart failure and for improving renal and cardiac diastolic functions in patients with renovascular hypertension complicated with heart failure.


en: 血圧日内変動を考慮したRAAS抑制薬による高血圧治療 (特集 血圧サーカディアンリズム : 24時間血圧管理の重要性) -- (24時間パーフェクト血圧管理をめざした治療)

en: Nihon Rinsho. Japanese Journal of Clinical Medicine

ja: 日本臨牀


en: 文献紹介「Stenting and medical therapy for atherosclerotic renal-artery stenosis」

en: 腎・高血圧の最新治療

ja: 腎・高血圧の最新治療


en: 用語解説 マイクロRNAと循環器疾患

ja: 用語解説 マイクロRNAと循環器疾患

en: Journal of JCS Cardiologists

ja: 循環器専門医


en: RAS研究 -ラボの最前線- 徳島大学大学院ヘルスバイオサイエンス研究部 循環器内科学・心臓血管病態医学

en: Angiotensin Research

ja: Angiotensin Research


en: Effects of Statins on Cardiorenal Syndrome.

en: Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS.

en: International Journal of Vascular Medicine


en: Pre-clinical data on the role of mineralocorticoid receptor antagonists in reversing vascular inflammation.

en: European Heart Journal Supplements

ja: European Heart Journal Supplements


en: Transforming Growth Factor-1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.

en: Transforming growth factor-1 (TGF-1) is a polypeptide member of the transforming growth factor superfamily of cytokines. It is a secreted protein that performs many cellular functions including control of cell growth, cell proliferation, cell differentiation and apoptosis. In the cardiovascular system, TGF-1 plays pivotal roles in the pathogenesis of hypertension, restenosis after percutaneous coronary intervention, atherosclerosis, cardiac hypertrophy and heart failure. In addition, TGF-1 has been shown to be increased in adipose tissue of obese subjects with insulin resistance. Furthermore, TGF-1 is a potent initiator of proliferation of renal mesangial cells leading to chronic kidney disease. Some currently available agents can manipulate TGF-1 expression leading to amelioration of cardiovascular diseases. Thus, an understanding of interactions between chronic kidney disease and metabolic syndrome and the development of cardiovascular diseases is an important issue, and attention should be given to TGF-1 as a crucial factor for regulation and modulation of those pathological conditions.

en: Cardiology Research and Practice

ja: Cardiology Research and Practice


en: 徳島大学病院での心臓リハビリテーションの現状

ja: 徳島大学病院での心臓リハビリテーションの現状

en: 心臓リハビリテーション

ja: 心臓リハビリテーション

misc_type: others